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Abstract
Background: The APOBEC3 family of cytidine deaminases mutate the cancer genome in a range of cancer
types. Although many studies have documented the downstream effects of APOBEC3 activity through
next-generation sequencing, less is known about their upstream regulation. In this study, we sought to
identify a molecular basis for APOBEC3 expression and activation.
Results: HER2 amplification and PTEN loss promote DNA replication stress and APOBEC3B activity in vitro and
correlate with APOBEC3 mutagenesis in vivo. HER2-enriched breast carcinomas display evidence of elevated
levels of replication stress-associated DNA damage in vivo. Chemical and cytotoxic induction of replication
stress, through aphidicolin, gemcitabine, camptothecin or hydroxyurea exposure, activates transcription of
APOBEC3B via an ATR/Chk1-dependent pathway in vitro. APOBEC3B activation can be attenuated through
repression of oncogenic signalling, small molecule inhibition of receptor tyrosine kinase signalling and
alleviation of replication stress through nucleoside supplementation.
Conclusion: These data link oncogene, loss of tumour suppressor gene and drug-induced replication stress
with APOBEC3B activity, providing new insights into how cytidine deaminase-induced mutagenesis might be
activated in tumourigenesis and limited therapeutically.
Keywords: APOBEC, Genomic instability, Replication stress, Somatic mutation
Significance
APOBEC3 mutates the cancer genome in a broad
range of cancer types. In this study we link DNA
replication stress mediated by oncogene activation or
cytotoxic exposure to APOBEC3B activity. These
insights provide support for therapeutic approaches
that might limit the activity of this mutagenic
process.
Background
Genomic instability is a well-recognized hallmark of can-
cer and is known to cause both aberrant chromosome
architecture as well as mutational changes at the single
nucleotide level [1]. We have previously identified a role
for DNA replication stress in human tumourigenesis [2, 3]
and in the generation of chromosomal instability, which
contributes to intratumour heterogeneity [4, 5]. More
recently, analyses performed in over 30 cancer types
have identified that many tumours exhibit cytosine mu-
tation biases, particularly C to T transitions and C to G
transversions predominantly in TCA or TCT trinucleo-
tide contexts [6–9]. The mutagen has been identified as
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a member of the apolipoprotein B mRNA editing
enzyme, catalytic polypeptide-like 3 (APOBEC3) family
of cytidine deaminases [9–11]. We recently described
the enrichment of APOBEC3 mutagenesis later in
tumour evolution, occurring as subclonal mutations in
estrogen receptor (ER)-negative breast cancer, lung
adenocarcinoma, head and neck squamous carcinoma
and bladder carcinoma, suggesting APOBEC3 may
contribute to branched evolution in some tumour types
[12–14].
Although, the involvement of APOBEC3 in cancer has
been refined over the past few years, the functional regula-
tion of this family of enzymes is yet to be fully understood.
A closer examination of kataegis in cancer samples revealed
that APOBEC3-induced mutations often colocalised with
breakpoint rearrangements, and within breast cancer, the
HER2-enriched (HER2+) subtype has been shown to dis-
play evidence of APOBEC3-mediated mutagenesis [9]. Fur-
thermore, HER2+ breast cancer is associated with high
levels of somatic copy number aberrations (SCNAs) [9].
Whether there is a mechanistic connection between the
underlying causes of chromosomal copy number aberra-
tions and the generation of APOBEC3 mutagenesis in
HER2+ breast cancer has not been explored.
The extent of hypermutation is likely to be dependent on
both the level of APOBEC3 protein and the availability of
single-stranded DNA (ssDNA) substrate [9]. In the presence
of cellular cytidine deaminase, however, the rate-limiting
step is thought to be substrate availability [15]. It is thought
that segmental SCNA breakpoints could potentially expose
more ssDNA, which is the ideal substrate for APOBEC3
[15, 16]. The availability of ssDNA substrate can be modu-
lated by regulating replication fork stability and collapse
[17]. Additional processes that induce ssDNA exposure in-
clude oncogene-induced replication stress, double strand
break (DSB) repair [18], R-loops formed during transcrip-
tion [19] and telomere crisis [20]. ssDNA can also be ex-
posed by DNA end resection during DSB repair [15]. In
addition, Gordenin and colleagues [16] previously identified
that the extent of strand-coordinated mutation clusters in
yeast was increased following exposure of cells to the chem-
ical mutagen methyl-methanesulfonate.
In this study, we investigated the genomic correlates of
APOBEC3 mutagenesis in breast cancer. We examined
whether DNA damage signalling, triggered by ssDNA ex-
posure by cytotoxic agents or oncogenic signalling, may
contribute to APOBEC3 activation and the mutational sig-
nature profile seen in breast cancer.
Results
HER2 amplification, PTEN and NF1 somatic mutations are
associated with the APOBEC3 signature
It has recently been shown that HER2-enriched (HER2+)
breast cancers are associated with a high burden of
mutations attributable to APOBEC3B [9]. We utilized
breast cancer samples from The Cancer Genome Atlas
(TCGA; n = 755) [21], which were subclassified using the
PAM50 algorithm into HER2+, basal, luminal A and lu-
minal B subtypes [22], and assessed the fold enrichment of
APOBEC3 signature mutations in each sample. Consistent
with a previous report [9], the APOBEC3 mutagenesis pat-
tern was significantly associated with the HER2+ subtype
(p value = 1.086 × 10−5, chi-square test; Fig. 1a, b). We also
observed that HER2 amplification was significantly associ-
ated with ‘APOBEC high’ samples in the luminal A subtype
(false discovery rate (FDR) q-value = 0.075, permutation
test; see “Methods”), implicating HER2 as a driver of APO-
BEC3 mutagenesis in this subtype (Fig. 1c). Additionally,
mutations in TP53, CDH1, NCOR1, PTEN and NF1,
CCND1 amplification, as well as loss of TP53 and KMT2C
were associated (FDR q-value <0.1, permutation test) with
‘APOBEC high’ samples in different breast cancer subtypes
(Fig. 1c), which could explain the heterogeneity in APO-
BEC3 enrichment among samples within subtypes. Muta-
tions in PIK3CA were also associated with the APOBEC3
signature, although it has been suggested that APOBEC3
activity itself is the main driver of these helical domain
mutations [23]. We further observed that ‘APOBEC high’
tumours had a higher number of segmental SCNA break-
points per sample compared with ‘APOBEC low’ tumours
(p value = 0.000343, Mann–Whitney U test; Additional
file 1: Figure S1a).
We examined APOBEC3A, APOBEC3B and APOBEC3G
mRNA expression levels in a panel of 15 breast cancer cell
lines (five luminal, five basal and five HER2+) by quantita-
tive PCR (Fig. 2a). Most luminal cell lines (green) exhibited
low levels of APOPEC3B mRNA expression, whereas most
of the HER2+ (red) exhibited higher APOBEC3B mRNA
levels (Fig. 2a). Basal cell lines (black) exhibited variable
APOBEC3B mRNA levels (Fig. 2a). APOBEC3B expression
was undetectable in SKBR3 cells, which are known to have
a homozygous deletion of APOBEC3B. The basal mRNA
expression of APOBEC3A and APOBEC3G was almost un-
detectable in all cell lines tested (Fig. 2a). The observed
mRNA expression levels were comparable to those identi-
fied in the Cancer Cell Line Encyclopedia (CCLE) dataset
(Additional file 1: Figure S1b). We also examined the de-
amination activity present in these cell lysates determined
using an oligonucleotide-based cytidine deamination assay
[10] using two probes whose activity is dependent on APO-
BEC3B (Fig. 2b; Additional file 1: Figure S1c–f). There was
a significant correlation between APOBEC3B expression
and activity in these cell lines (r = 0.8, p = 0.0016, Spearman
rank correlation test; Additional file 1: Figure S1g).
Since HER2 signalling is known to drive a proliferative
phenotype, which might provoke elevated DNA replicative
stress (reviewed in [24]), we next investigated markers of
DNA replicative stress in the 15 breast cancer cell lines.
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Immunofluorescence analysis using 53BP1 nuclear bodies
in G1 as a marker of DNA replication stress [25] revealed
that cell lines with higher levels of APOBEC3B expression
had significantly higher levels of replication stress (r = 0.62,
p = 0.0284, Spearman rank correlation test; Fig. 2c;
Additional file 1: Figure S1h). SKBR3 (APOBEC3B null) and
MDA-MB-361 (with a missense mutation in 53BP1) cell
lines were both excluded from the analysis. To further con-
firm the relevance of DNA replication stress in APOBEC3
activation, we investigated whether alleviating replication
stress would reduce APOBEC3 activity. Previously, it has
been shown that supplementation of exogenous nucleosides
increases the nucleotide pool in the cell and can rescue
replication stress [26, 27]. Therefore, we treated BT474
cells, a HER2-amplified cell line with elevated DNA repli-
cation stress (Fig. 2c), with exogenous nucleosides prior to
performing the oligonucleotide-based deamination assay.
Treatment with 12.5–300 μM nucleosides for 72 h led to a
significant reduction in the basal levels of APOBEC3B pro-
tein and activity in a dose-dependent manner (Fig. 2d, e).
Supplementation of MDA-MB-134 cells (a luminal cell line
with low but detectable APOBEC3 activity) with exogenous
nucleosides also led to a reduction in basal APOBEC3 ac-
tivity (Additional file 2: Figure S2d). No correlation was ob-
served between reductions in cell viability in response to
300-μM nucleoside treatment (Additional file 1: Figure S1i;
Additional file 3: Figure S3b) and the induction of APO-
BEC3 activity. Nucleoside supplementation reduced the S
phase population in MDA-MB-134 cells but had minimal
effect on the cell cycle distribution of BT474 cells
(Additional file 1: Figure S1j; Additional file 4: Figure S4d).
Taken together these results implicate the involve-
ment of DNA replication stress in APOBEC3-mediated
mutagenesis.
Replication stress induced by cytotoxic drugs leads to
APOBEC3 induction
In order to decipher the mechanism through which replica-
tion stress is implicated in the induction of APOBEC3 ac-
tivity, we tested a panel of cytotoxic drugs known to induce
Fig. 1 APOBEC3 mutational signatures and associated genes in breast cancer subtypes. a Violin plots showing APOBEC3 mutagenesis fold enrichment.
The purple diamond represents the median in each subtype. b Boxplots showing percentage of ‘APOBEC high’ (red) and ‘APOBEC low’ (blue) samples in
each subtype. Asterisks represent a significant p value <0.05 from pairwise post hoc tests. c Single-nucleotide variants (SNVs) and SCNAs associated with
‘APOBEC high’ tumour samples. Bars denote proportion of ‘APOBEC high’ (red) and ‘APOBEC low’ (blue) samples harbouring mutation. Amplification
and loss refer to ≥2× ploidy and ≤1 copy number relative to ploidy, respectively. An asterisk denotes significant association in subtype (q < 0.1 by
permutation test, corrected for analysis of multiple genes by the Benjamini–Hochberg method). Note differing scales used on the y-axis. Lum luminal
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either DSB or ssDNA damage. MCF10A cells were treated
with nine drugs with broad DNA damaging or anti-
metabolite activity (hydroxyurea, aphidicolin, cisplatin,
gemcitabine, etoposide, camptothecin, methylmethanesul-
fonate, doxorubicin and 5-fluorouracil) for 48 h, after which
APOBEC3 mRNA expression, protein and activity levels
were assessed. Treatment of MCF10A cells with hydroxy-
urea, aphidicolin, gemcitabine and camptothecin elicited an
increase in both APOBEC3B and APOBEC3G mRNA ex-
pression (Fig. 3a), APOBEC3B protein expression (Fig. 3b)
and APOBEC3 activity (Fig. 3c; Additional file 2: Figure S2a;
Additional file 5: Figure S5). Treatment of MCF7, HCC1419
and MDA-MB-134 cells with hydroxyurea, aphidicolin and
gemcitabine also led to an increase in APOBEC3 activity
(Additional file 2: Figure S2b–d). SKBR3 cells were included
as a negative control (Additional file 2: Figure S2e). By per-
forming the cytidine deamination assays following depletion
of APOBEC3B by RNA interference (RNAi), we confirmed
that all detectable hydroxyurea-induced deamination activity
in the breast cancer cell lines was attributable to APOBEC3B
(Additional file 2: Figure S2f, g). No correlation was ob-
served between drug-induced cytotoxity (Additional file 3:
Figure S3a–d) and APOBEC3 activity. We observed that the
four cytotoxic drugs that elicited the highest levels of APO-
BEC3B induction were associated with S phase enrichment
in HCC1419 and MDA-MB-134 cells. Cell cycle arrest in
MCF10A cells was also associated with an accumulation of
cells at G2/M (Additional file 4: Figure S4).
In order to investigate the type of DNA damage induced
by drug exposure, we assessed the extent of DSBs and
ssDNA damage caused by these drugs by immunofluores-
cence staining of Ser139 γH2AX and pS4/8 replication
protein A (RPA), respectively (Fig. 3d; Additional file 6:
Figure S6a). There was a significant correlation between
the drugs that caused the highest APOBEC3B induction
and the induction of RPA phosphorylation in MCF10A
cells (Additional file 6: Figure S6b–d). The four drugs that
induced APOBEC3B activity all induced the highest
levels of RPA phosphorylation in MCF10A cells (Fig. 3d),
whereas in MCF7 cells this was only the case for three out
of the four drugs (Additional file 6: Figure S6a). There was
no correlation between drugs inducing DSBs and APOBEC3
induction. Furthermore, we observed that exposure of
MCF10A cells to exogenous nucleosides also attenuated the
Fig. 2 APOBEC3 activity and replication stress in breast cancer cell lines. a APOBEC3B (black), APOBEC3G (grey) and APOBEC3A (white) mRNA expression
in 15 breast cancer cell lines as determined by quantitative PCR. HER2+ cell lines (red), basal cell lines (black), luminal cell lines (green). SKBR3 cells have
a null mutation for APOBEC3B. Error bars represent standard deviation. b APOBEC3 activity in the 15 breast cancer cell lines used in a. Cells were lysed
and subjected to oligonucleotide-based cytidine deamination assay followed by electrophoresis on 15 % TBE-urea gels. c Cells were grown for two
population doublings on glass coverslips followed by fixation and staining with 53BP1 and cyclin A antibodies. The fractions of cyclin A-negative cells
displaying more than five 53BP1 nuclear foci were scored. APOBEC3B mRNA expression was determined by quantitative PCR from parallel cell lysates. A
Spearman’s rank correlation test was performed to correlate the fraction of 53BP1 nuclear bodies in cell lines with the level of APOBEC3B (r = 0.62, p =
0.0284). Error bars represent standard deviation. d BT474 cells were treated with 12.5–300 μM nucleosides for 72 h prior to lysis. Western blots were
probed with the indicated antibodies. e BT474 cells were treated as in d followed by lysis and an APOBEC3 cytidine deamination assay
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hydroxyurea, aphidicolin and gemcitabine-induced increase
in APOBEC3 activity (Fig. 3e). Nucleoside supplementation
reduced the hydroxyurea-induced S phase enrichment in
MCF10A cells (Additional file 3: Figure S3e). These results
suggest that DNA replication stress is able to increase APO-
BEC3 transcription levels and trigger its activity.
Hydroxyurea is an inhibitor of ribonucleotide reductase,
an enzyme that catalyses the reduction of ribonucleotides
to deoxyribonucleotides, which are required for DNA rep-
lication. Depletion of ribonucleotide reductase stalls the
DNA polymerase at the replication forks, resulting in DNA
replication stress [28]. In order to further confirm the role
for DNA replication stress in APOBEC3 regulation, we de-
pleted ribonucleotide reductase subunits RRM1, RRM2
and RRM2B by small interfering RNA (siRNA) in MCF10A
cells since they exhibit low levels of basal APOBEC3B ac-
tivity and replication stress. Knockdown of either RRM1 or
RRM2 subunits by siRNA led to an increase in APOBEC3B
deamination activity (Fig. 3f; Additional file 6: Figure S6e).
Knockdown of RRM2B encoding the small subunit of p53
Fig. 3 Induction of replication stress and APOBEC3 activity in breast cancer cell lines. a MCF10A cells were treated with the indicated drugs for 48 h
followed by mRNA extraction, cDNA synthesis and quantitative PCR for APOBEC3B and APOBEC3G expression levels. b MCF10A cells were treated as in
a followed by western blotting with the indicated antibodies. c MCF10A cells were treated as in a prior to lysis and a cytidine deamination assay for
APOBEC3 activity using probe 2. d MCF10A cells were treated as in a followed by fixation and immunofluorescence for Ser139 γH2AX and
S4/8 replication protein A phosphorylation (pRPA). Red asterisks indicate treatments inducing APOBEC3B mRNA, protein expression, activity
levels and S4/8 RPA phosphorylation. e MCF10A cells were pre-treated with 300 μM exogenous nucleosides followed by incubation with the indicated
drugs for an additional 24 h. Following lysis, APOBEC3 activity was measured by a cytidine deamination assay. f Ribonucleotide reductase subunits RRM1,
RRM2 and RRM2B were depleted from MCF10A cells by RNA interference and, after 72 h, cells were lysed and subjected to an APOBEC3 cytidine
deamination assay. 5FU 5-fluorouracil, MMS methyl methanesulfonate, siNT non-targeting control siRNA
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inducible ribonucleotide reductase had no effect. These re-
sults suggest a relationship between the induction of
ssDNA and APOBEC3B induction.
HER2 expression and PTEN knockdown contribute to
APOBEC3 activity
Having observed increased replication stress and APOBEC3
activity in many of the HER2+ cell lines, we next investi-
gated the consequence of HER2 depletion on APOBEC3
activity using the oligonucleotide-based deamination assay.
Silencing HER2 by RNAi in HER2+ BT474 and MDA-MB-
361 cells led to a reduction in APOBEC3B mRNA expres-
sion, protein levels and deamination activity (Fig. 4a–c;
Additional file 7: Figure S7a). To further examine whether
this reduction was dependent on the presence of HER2
protein or on HER2 downstream signalling, APOBEC3B
mRNA expression, protein and activity levels were assessed
following exposure of HER2+ cells to HER2 tyrosine kinase
inhibitors. A 24-h treatment of BT474 cells with 10
nM afatinib and 30 nM lapatinib resulted in reduced
Fig. 4 (See legend on next page.)
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APOBEC3B mRNA expression (by 64 % and 42 %, re-
spectively), protein and deamination activity (Fig. 4d–f;
Additional file 7: Figure S7b). There was no correlation
between treatment-induced cytotoxicity and APOBEC3
induction (Additional file 8: Figure S8a). Treatment with
lapatinib reduced the S phase population, whereas afatinib
did not significantly alter the cell cycle distribution of
BT474 cells (Additional file 8: Figure S8c). In addition,
lapatinib treatment was able to reduce hydroxyurea-
induced APOBEC3B transcription and activity in HER2+
HCC1419 (Additional file 7: Figure S7c–f ). These results
suggest that signal transduction cascades downstream of
HER2 could be implicated in APOBEC3 induction.
We next investigated the requirement for phos-
phatidylinositol 3-kinase (PI3K), mitogen-activated pro-
tein kinase (MAPK), AKT and mammalian target of
rapamycin (mTOR) signalling pathways on replication
stress-induced APOBEC3 activation. First MCF10A cells,
with a low basal level of replication stress, were treated
with hydroxyurea in the presence of inhibitors of these sig-
nalling pathways for 24 h. Inhibition of MEK signalling
(with U0126) and to a lesser extent mTOR signalling (with
rapamycin) attenuated hydroxyurea-induced APOBEC3G
transcription and APOBEC3 activity (Fig. 4g; Additional
file 8: Figure S8d), implicating both arms of the signalling
cascade in the exacerbation of DNA replication stress-
induced APOBEC3 mutagenesis. Consistent with this find-
ing, treatment of MDA-MB-453, HCC1569 and BT474
cells with U0126, rapamycin and LY294002 also led to a
reduction in basal APOBEC3 activity (Fig. 4h; Additional
file 8: Figure S8e, f ). There was no correlation between the
extent of cytotoxicity of the drugs and their ability to in-
duce APOBEC3 activity (Additional file 8: Figure S8b;
Additional file 9: Figure S9a). In BT474 cells treatment
with UO126 and rapamycin appeared to reduce the G2/M
phase (Additional file 8: Figure S8c). In MCF7 cells hy-
droxyurea appeared to induced cell cycle arrest in the S
and G2/M phases, which could be rescued with rapamycin
treatment (Additional file 9: Figure S9b). Since we identi-
fied that PTEN mutations were also associated with en-
richment of the APOBEC3 mutational signature, we also
investigated the effect of PTEN loss on replication stress-
induced APOBEC3 activity. MCF7 cells were depleted of
PTEN by siRNA and replication stress was assessed by
scoring the presence of G1 nuclear bodies. Silencing of
PTEN led to a significant increase in G1 bodies from 21 to
48 % (p value = 0.027, t-test; Fig. 4i) and an increase in
APOBEC3B protein and cytidine deamination activity
(Fig. 4j; Additional file 9: Figure S9c, d). PTEN knockdown
did not cause a significant change in cell viability or a
change in cell cycle distribution that could account for the
increase in APOBEC3 activity observed (Additional file 9:
Figure S9e, f ).
Oncogene-induced replication stress and APOBEC3
activation
Overexpression of several oncoproteins, including RAS,
MYC, CCND1 and CCNE, has been demonstrated to cause
increased origin firing and increased proliferation by acceler-
ating G1/S transition leading to replication stress [3, 29–32].
To determine if oncogene-induced replication stress would
also lead to APOBEC3 activation, we treated an MCF10A
cell line stably expressing a 4-hydroxytamoxifen-inducible
oncogenic RAS chimeric protein, ER:HRAS V12 [33], with
hydroxyurea and assessed APOBEC3 activation. Treatment
of MCF10A-ER:HRAS V12 cells with 2 mM hydroxyurea
increased APOBEC3B mRNA expression approximately 20-
fold, which was not further increased by the activation of
RAS V12 (Fig. 4k). RAS V12 induction in the absence of hy-
droxyurea led to a modest increase in APOBEC3 deamin-
ation activity relative to non-induced cells (Fig. 4l). RAS
V12 induction in the presence of hydroxyurea also led to a
modest increase in APOBEC3 deamination activity com-
pared with hydroxyurea treatment alone. These results
(See figure on previous page.)
Fig. 4 HER2 expression and PTEN contribute to APOBEC3 activity. a APOBEC3B mRNA expression following silencing of HER2 expression in BT474
cells by RNAi. HER2 levels were depleted by RNAi and, after 72 h, cells were harvested and mRNA extracted. Following cDNA synthesis, APOBEC3B
mRNA levels were determined by quantitative PCR; *p < 0.01 (t-test). siNT non-targeting control siRNA. b BT474 cells were treated as in a and, following
lysis, western blots were probed with the indicated antibodies. c BT474 and MDA-MB-361 cells were treated as in a and, following lysis, samples were
subjected to cytidine deamination assay to determine levels of APOBEC3 activity. d BT474 cells were treated with 10 nM afatinib or 30 nM lapatinib for
24 h followed by mRNA isolation and quantitative PCR to determine APOBEC3B mRNA expression levels; *p < 0.01, ***p < 0.005 (t-test). e BT474 cells
were treated as in d and, following lysis, western blots were probed with the indicated antibodies. f BT474 cells were treated as in d and, following lysis,
samples were subjected to cytidine-based deamination assay to determine levels of APOBEC3 activity. g MCF10A cells were treated with or without 2
mM hydroxyurea (HU) and exposed to the indicated drugs for 48 h followed by APOBEC3 cytidine deamination assay. h MDA-MB-453 cells were treated
with the indicated drugs for 48 h followed by APOBEC3 cytidine deamination assay. i PTEN levels were depleted from MCF7 cells growing on
glass coverslips by RNAi. Cells were fixed and stained with 53BP1 and cyclin A antibodies. The fraction of cyclin A-negative cells displaying
more than five 53BP1 nuclear foci were scored; *p < 0.05 (t-test). j PTEN levels were depleted from MCF7 cells by RNAi. After 72 h cells were
harvested and samples were subjected to cytidine deamination assay to determine APOBEC3 activity. k APOBEC3 activity in response to RAS
induction and hydroxyurea (HU) treatment. MCF10A-ER:HRAS V12 cells were induced with tamoxifen (4-hydroxytamoxifen; 4- OHT) in either
the presence or absence of hydroxyurea for 48 h, followed by mRNA isolation, cDNA synthesis and quantitative PCR to determine APOBEC3B expres-
sion levels. l MCF10A-ER:HRAS V12 cells were treated as in k. Cells were subsequently lysed and subjected to APOBEC3 cytidine deamination assay. LY
LY294002, MK MK2206, NT non-targeting, RAPA rapamycin, UNT untreated
Kanu et al. Genome Biology  (2016) 17:185 Page 7 of 15
illustrate that RAS hyperactivation alone is insufficient to
significantly activate APOBEC3 in this system.
ATR pathway implicated in APOBEC3 regulation
Since DNA replication stress activates the ataxia tel-
angiectasia mutated and Rad3-related protein (ATR)/
Checkpoint kinase 1 (Chk1) response, we investigated
whether these kinases may mediate APOBEC3 activity
following hydroxyurea-induced DNA replication stress.
MCF10A cells were first treated with ATR and ATM
kinase inhibitors and APOBEC3 activity was assessed.
Inhibition of ATR and to a lesser extent ATM led to a
reduction of the hydroxyurea-induced APOBEC3 acti-
vation (Fig. 5a). Furthermore, treatment of MDA-MB-
453 and BT474 cells with the novel specific Chk1 inhibitor
CCT244747 [34] led to a reduction of basal APOBEC3 ac-
tivity (Fig. 5b; Additional file 10: Figure S10a). Similarly,
treatment of MCF10A cells with CCT244747 led to a re-
duction in hydroxyurea-induced APOBEC3B protein and
activity (Fig. 5c, d). In addition, MCF10A cells were de-
pleted of ATR or CHEK1 by siRNA and subsequently APO-
BEC3 activity was measured under basal conditions and in
response to hydroxyurea treatment. In the control siRNA
transfected cells, hydroxyurea treatment caused robust
APOBEC3 activation; in contrast, this response was re-
duced following depletion of ATR or CHEK1 (Additional
file 10: Figure S10b, c). Consistent with these findings,
Chk1 inhibition using an alternative Chk1 inhibitor,
UCN01, also prevented the hydroxyurea-dependent in-
crease in APOBEC3B transcription (Additional file 10:
Figure S10d). Interestingly, APOBEC3B expression corre-
lated with sensitivity to the Chk1 inhibitor CCT244747
(Additional file 10: Figure S10e). There was no correlation
between drug-induced cytotoxicity or changes in cell cycle
Fig. 5 DNA damage signalling and APOBEC3 activity in breast cancer cell lines. a MCF10A cells were treated with ATM or ATR inhibitors for 24 h
after which cells were treated with hydroxyurea (HU) for a further 48 h prior to lysis and cytidine deamination assay for APOBEC3 activity. b MDA-
MB-453 cells were treated for 48 h with the indicated doses of Chk1 inhibitor CCT244747 followed by APOBEC3 cytidine deamination assay. c MCF10A
cells were treated for 48 h with the indicated doses of Chk1 inhibitor CCT244747 and with 2 mM hydroxyurea for the last 24 h. Following lysis, western
blots were probed with the indicated antibodies. d MCF10A cells were treated as in c before lysis and cytidine deamination assay to determine APOBEC3
activity. e Model illustrating mechanisms of APOBEC3 regulation by replication stress. CTRL control, UNT untreated
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distribution and APOBEC3 levels following treatment
with the ATR, ATM or Chk1 inhibitors (Additional file 9:
Figure S9b; Additional file 10: Figure S10f–h).
Elevated replication stress-associated DNA damage in
HER2-positive breast carcinomas
Since we observed that most HER2+ cell lines exhibited
high levels of APOBEC3B mRNA expression and replica-
tion stress-associated G1 nuclear bodies, we next investi-
gated whether the same characteristics were observed in
vivo. We performed immunohistochemical analysis on
sections from formalin-fixed, paraffin-embedded material
from a clinical cohort of breast carcinomas and adjacent
normal breast tissue with antibodies against γH2AX and
phosphorylated RPA (RPA-P), markers of DNA damage
and ATR signalling, respectively (Additional file 11: Figure
S11a). We also tested commercially available APOBEC3B
antibodies for suitability in immunohistochemistry but
none were sufficient to reliably and specifically detect nu-
clear APOBEC3B. Compared with luminal breast tu-
mours, the HER2+ tumours exhibited significantly higher
proportion of samples with more than 10 % of cells stain-
ing positive for γH2AX (p = 3.3e-06, Fishers exact test;
Additional file 11: Figure S11b). HER2+ tumours also ex-
hibited more RPA-P than normal breast tissue (Additional
file 11: Figure S11c). In addition, all but one case among
the tumours exhibiting a high proportion of cancer cells
positive for the γH2AX marker showed concomitant high
levels of RPA-P, suggesting that replication stress contrib-
utes to the DNA damage observed in the HER2+ tumours.
These results strengthen our conclusion that HER2+ tu-
mours, which are associated with the highest mutational
load of APOBEC3 mutations, exhibit high levels of repli-
cation stress-associated DNA damage.
Discussion
The APOBEC3 mutational signature has been found in a
range of different cancer types and is one of the most
frequently occurring mutational signatures in the cancer
genome [6]. It is not clear how APOBEC3 influences
tumour evolution but it is hypothesized to increase the
fitness of cancer cells by providing the beneficial gain of
oncogene or loss of tumour suppressor gene function
[23] and is associated with the progressive acquisition of
subclonal mutations later in tumour evolution in some
cancer types [13]. In breast cancer, the HER2+ subtype
is especially affected by TCW mutations, indicating that
APOBEC3 has been active during the progression of this
disease [9]. It was found that HER2-amplified [9] and
HER2-overexpressing tumours [35] harbour a high
SCNA load, suggesting that HER2 might underlie the
formation of SCNAs and APOBEC3 activity.
In addition to the activity of APOBEC3, the localization
of APOBEC3 family members is also regulated. The
subcellular localization of APOBEC3 family members has
been evaluated using a series of green fluorescent protein
fusion constructs [36–38]. In contrast to APOBEC3B,
which is predominantly nuclear, APOBEC3G is cytoplas-
mic under steady state conditions [36–38]. However, in
lymphoma cells APOBEC3G has been shown to enter the
nuclear compartment as part of a DNA damage response
and promote DNA repair by activating the ataxia telangi-
ectasia mutated (ATM) DNA damage checkpoint kinase
[39]. These data suggest potential roles for multiple APO-
BEC3 members in response to DNA damage and replica-
tion stress.
In this study, we first investigated the correlation be-
tween basal APOBEC3 activity and HER2 status. We
identified a trend towards HER2-enriched breast cancer-
derived cell lines having high basal APOBEC3 activity.
The high levels of APOBEC3 activity in the HER2+ sub-
type indicates that an increased gene dosage of ERBB2
may drive APOBEC3 in breast cancer, corroborating
earlier observations by Roberts and colleagues [9].
Nevertheless, apart from ERBB2 amplifications we ex-
pect other oncogenes to drive APOBEC3 activity by
virtue of their impact on DNA replication stress. Onco-
gene activation can induce replication stress in several
different ways, including interfering with the timing and
number of origins firing [30, 32]. Furthermore, oncopro-
teins such as cyclin E may also induce replication stress
via inactivation of retinoblastoma protein and enhanced
S phase entry [2, 3]. Overexpression of RAS causes an
initial hyperproliferation accelerating G1/S phase transi-
tion and we identified that PI3K and MAPK signalling
contribute to APOBEC3 activity in multiple different
breast cancer cell lines. This is consistent with previous
data reporting the ERK signalling pathway is involved in
the regulation of APOBEC3G in human T lymphocytes
[40]. We also investigated APOBEC3 activity before and
after RAS hyperactivation in MCF10A-ER:HRAS cells.
RAS hyperactivation modestly induced APOBEC3 activity
in these cells, suggesting that it could be insufficient to ro-
bustly activate APOBEC3 in tumours on its own. Since in-
hibition of both PI3K and MAPK pathways was shown to
reduce APOBEC3 activity, one possibility is that both sig-
nalling pathways are required to activate APOBEC3 levels.
Interestingly, we identified that mutations in PTEN and
NF1 were also associated with APOBEC3 mutation en-
richment in the different breast cancer subtypes, further
implicating PI3K and MAPK signalling in co-regulating
APOBEC3 mutagenesis in breast cancer. Recent reports
also show NFkB signalling plays a role in the regulation of
APOBEC3B [41] and AID [42]. It is likely, therefore, that
additional pathways drive APOBEC3 activity in cancer.
In addition to genetic and signalling factors, we identi-
fied that specific drugs can activate APOBEC3 activity. We
found that exposure of cells to hydroxyurea, aphidicolin,
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gemcitabine and camptothecin resulted in enhanced APO-
BEC3 activity. These drugs were modestly associated with
S phase enrichment. A similar observation was made in
yeast after exposure to hydroxyurea [43]. These treatments
also resulted in the highest levels of RPA-P, indicative of
increased exposure of ssDNA. Hydroxyurea and gemcita-
bine can both inhibit ribonucleotide reductase, aphidicolin
inhibits DNA polymerase alpha whereas camptothecin is
a topoisomerase I inhibitor. As the extent of RPA-P
achieved was highest with these drugs, we speculate that
the differentiation between these drugs and the other
tested DNA damaging agents is their ability to induce suf-
ficient ssDNA provoking downstream DNA replication
stress detection in order to surpass the threshold of ATR
signalling required for APOBEC3 activation. Our findings
might have clinical implications as we show that several
clinically used cytotoxic drugs may induce APOBEC3 ac-
tivity. Future studies should test the ability of other cyto-
toxic drugs to induce APOBEC3 activity and investigate
whether relapse samples contain more therapy-induced
APOBEC3 mutations.
Besides inducing APOBEC3 activity, we were also able
to diminish APOBEC3 activation through supplementing
growth media with exogenous nucleosides, which is
known to rescue DNA replication stress and genomic in-
stability [26, 27]. In addition we show that APOBEC3 ac-
tivation is coordinated by a transcriptional response
downstream of the key signalling cascades governed by
ATR/ATM and this signalling can be rescued by exogen-
ous nucleoside supplementation. These data implicate a
role for replication-associated damage in triggering the
transcriptional response to APOBEC3 activation. Interest-
ingly, we found that two different Chk1 inhibitors potently
inhibited APOBEC3 activity. Since ATR/Chk1 inhibition
would lead to a failure to signal the presence of exposed
ssDNA, these data are consistent with a role for this signal-
ling cascade in mediating the DNA replication stress-
invoked pathway following ssDNA exposure to APOBEC3
mRNA transcriptional activation. These findings are of po-
tential clinical relevance as an analogue of CCT244747 will
soon be tested in a phase 1 clinical trial and biomarkers of
response to therapy are actively under investigation [44].
Additionally, we found a trend between APOBEC3B ex-
pression and sensitivity to CCT244747 (p value = 0.058,
Spearman rank correlation test; Additional file 10:
Figure S10e), which further strengthens the potential
clinical relevance of our findings. We speculate that high
levels of replication stress results in the activation of Chk1
and the subsequent induction of APOBEC3 activity. These
cells exhibit high levels of DNA replication stress and are,
therefore, more likely to be dependent on Chk1 signalling
for repair [45], which may explain why we observe that
cells with high APOBEC3 activity appear more sensitive to
Chk1 inhibition. We speculate that more direct gene
expression biomarkers, apart from APOBEC3B, could po-
tentially be of use to predict response to CCT244747. Al-
though more research is needed, we speculate that
whereas replication stress-induced APOBEC3B regulation
could contribute to a portion of APOBEC3-mediated mu-
tagenesis, APOBEC3G upregulation could enhance DNA
repair, as has been previously postulated in lymphoma cells
[39]. Our in vitro data are supported by our observation
that replication stress-associated DNA damage was signifi-
cantly associated with the HER2+ subtype, suggesting that
replication stress could potentially drive APOBEC3 activa-
tion in HER2+ breast carcinomas.
We recently showed in ER-negative breast cancer that
there is a modest increase in the APOBEC3 mutation
signature in later, subclonal mutations, implicating this
process in the exacerbation of intratumour heterogeneity in
ER-negative breast cancer [13]. Our current data suggests
that this late activation could be a response to altered levels
of replication stress (Fig. 5e). DNA replication stress and its
induction through mitogenic signalling could be a particu-
larly potent driver of genomic instability, inducing both
chromosomal instability and APOBEC3 activation (Fig. 5e).
Conclusions
These findings illustrate that DNA replication stress ap-
pears to be a particularly potent driver of genomic instabil-
ity in cancer. On the one hand, DNA replication stress has
been demonstrated to induce both structural and numer-
ical chromosomal aberrations generating chromosomal in-
stability [27]. In addition, we now propose that replication
stress is able to induce single nucleotide-level mutagenesis
mediated via APOBEC3B induction. These dual roles for
DNA replication stress in mediating genomic instability
could link the high level of SCNAs and single nucleotide
diversity caused by APOBEC3 activity that are both ob-
served in HER2+ tumours.
We have found that oncogenic signalling, cytotoxic drugs
and genetic modulators of replication stress are all able to
modulate APOBEC3 activity. These findings implicate the
ability of therapeutics that either attenuate oncogenic sig-
nalling or exacerbate DNA replication stress to alter can-
cer’s mutagenic landscape and evolutionary potential.
Methods
Cell lines
SKBR3, MCF7, HCC1419, HCC1569, HCC1954, T47D,
BT474, MDA-MB-231, MDA-MB-361, MDA-MB-453,
ZR75.1, MDA-MB-134, CAL51, HCC1428 cell lines were
obtained from The Francis Crick Institute, Cell services.
All cells were grown in RPMI 1640 media (ThermoFisher
Scientific), supplemented with 10 % foetal bovine srum
and 1/10,000 units of penicillin-streptomycin (Sigma-
Aldrich) and with L-glutamine (ThermoFisher Scientific).
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MCF10A cells were a kind gift from Almut Schulze.
MCF10A-ER:HRAS were a kind gift from Julian Down-
ward. MCF10A and MCF10A-ER:HRAS cells were grown
in DMEMF12 supplemented with 5 % horse serum, 10 μg/
ml insulin, 5 μg/ml hydrocortisone, 20 ng/ml epidermal
growth factor, 100 ng/ml cholera toxin and 1/10000 units
of penicillin-streptomycin. All cell lines used in this study
were maintained at 37 °C in 5 % CO2.
Treatments
Where indicated, cells were treated with 2 mM hydroxy-
urea, 2.5 μm aphidicolin, 10 μm etoposide, 10 μm 5-
fluorouracil, 1 μM cisplatin, 1 μM gemcitabine, 0.001 %
methyl methanesulfonate, 100 nM doxorubicin, 3 μM
camptothecin, 300 μM nucleosides, 10 nM afatinib, 30
nM lapatinib, 150 nM rapamycin, 15 μm MEK inhibitor
U0126, 150 nM AKT inhibitor MK2206, 7.5 μm PI3K
inhibitor LY294002, 1 μm ATR kinase inhibitor VE821
(AdooQ), CCT244747 (a kind gift from Prof. Ian Collins,
ICR, London), 10 μm ATM kinase inhibitor KU55933
(Merck, Millipore), 100 nM UCN01 Chk1/PKCβ inhibi-
tor (Merck, Millipore), 12.5–300 μM EmbryoMax Nu-
cleosides (Millipore).
RNA interference
All siRNA (Dharmacon, GE Healthcare) transfections
were performed at 40 nM final concentrations by reverse
transfection with Lipofectamine® RNAiMax (Thermo
Fisher Scientific): ATR (L-003202), CHEK1 (L-003255),
ERBB2 (LU-003126), RRM1 (LU-004270), RRM2 (LU-
010379), RRM2B (LU-010575), PTEN (J-003023), APO-
BEC3B (J-017322). Non-targeting (NT) control siRNA
was used as control in all experiments.
RNA extraction and reverse transcription PCR
RNA was extracted using a Qiagen RNeasy kit and then re-
verse transcribed to cDNA using an AffinityScript cDNA
synthesis kit (Agilent Technologies) according to the manu-
facturers’ instructions. Quantitative PCR was performed
with triplicates in 96-well plate format on the StepO-
nePlus Real-Time PCR system (ThermoFisher Scientific)
using pre-designed TaqMan® probes for APOBEC3B
(Hs00358981_m1) and APOBEC3G (Hs00222415_m1)
and ATR (Hs00992123_m1). RRM1, RRM2, RRM2B, PTEN
and CHEK1 quantitative PCR was performed using Quanti-
Tect SYBR Green PCR kits. mRNA expression levels were
quantified using the comparative Ct method, normalized to
DNA topoisomerase I (Hs00243257_m1).
Gel-based deamination assay using oligonucleotide probe
We seeded 200,000 cells per well in six-well plates. Cells
were allowed to adhere for 24 h, after which they were
treated with cytotoxic drugs or siRNAs for up to 72 h.
Cells were subsequently isolated and lysed in HED buffer
(25 mM HEPES, 5 mM EDTA, 10 % glycerol, 1 mM DTT
(added fresh) and protease inhibitor (added fresh)). The
protein concentrations were equalized and deamination re-
actions were performed at 37 °C for 3 h using the APO-
BEC3 probe 1 (5′-fluorescein-ATTATTATTATTATTCCC
AATTATTTATTTATTTATTTATTT) [46] or probe 2 (5′-
ATTATTATTATTCGAATGGATTTATTTATTTATTTAT
TTATTT-fluorescein-3′) in a 10× UDG reaction buffer
consisting of 1.25 μL RNaseA (0.125 mg/mL), 1 μL probe
(0.2 pmol/μL), 16.5 μL cleared lysate and uracil DNA gly-
cosylase (UDG; New England Biolabs, 1.25 units). We
added 100 mM NaOH and the sample was then incubated
at 95 °C for 30 minutes to cleave the abasic sites followed
by addition of formamide-based gel sample buffer. The re-
action product was run on a 15 % urea-TBE gel that was
imaged and quantified on an ImageQuant LAS 4000. Probe
1 was used in all experiments unless stated otherwise.
Cytotoxicity assay
The cytotoxicity of CCT244747 was determined using a
sulforhodamine-based growth delay assay. Cells were
plated at appropriate densities into 96-well plates and
allowed to attach for 36 h. Drug treatment was from 4
to 10 days to allow drug contact for at least two doub-
ling times followed by sulforhodamine B staining and 50
% growth inhibition (GI50) determination. GI50 values
were determined using Graph Pad Prism 6 software and
Spearman rank correlations were performed between
GI50 values against APOBEC3B mRNA expression and
APOBEC3 activity.
Flow cytometry analysis
Cells were washed in PBS and resuspended in PBS/0.1 %
bovine serum albumin (BSA) and DNA was stained with
propidium iodide. Samples were analyzed on a BD
LSRFortessa X-20 cytometer (BD Biosciences) and proc-
essed in FlowJo.
Cell viability assay
Treatment-induced cytotoxicity was determined using
the CellTiter-Glo luminescent cell viability kit (Promega)
in accordance with the manufacturer’s instructions.
Protein extraction and western blotting
Total cell lysates were generated as described previously
[47, 48]. Following SDS-PAGE, blots were probed with in-
dicated antibodies diluted in 5 % milk or BSA in Tris-
buffered saline. Antibodies: HER2 (Cell Signaling #2248),
pSer473 AKT (Cell Signaling #4060), total AKT (Cell Sig-
naling #2920), rabbit anti-APOBEC3B monoclonal anti-
body 5210-87-13 [41], HRP-conjugated anti-β-GAPDH
antibody (Abcam ab9482) and HRP-conjugated goat
anti-mouse/rabbit immunoglobulins (Dako). Immobilon
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Western Chemiluminescent HRP Substrate (Millipore) was
used for detection.
Immunofluorescence
Cells were treated and fixed as described previously [47].
Cells were stained with the indicated antibodies: 53BP1
(sc22760 Santa Cruz), cyclin A (in house), Ser139-γH2AX
(Millipore 05636), RPA32/RPA2 (phosphoS4 + S8, Abcam
ab87277). Anti-mouse and anti-rabbit IgG (H + L) Alexa
Fluor 488, 594 and 647 secondary antibodies were used at
1:500 dilution (ThermoFisher Scientific).
Archival tumour samples and immunohistochemistry
Formalin fixed, paraffin-embedded specimens of normal
breast tissue adjacent to tumour (n = 37) and breast car-
cinoma tissues (n = 120) from the tissue archive of the
Danish Cancer Society Research Center in Copenhagen
were examined. All tissue samples were collected from pa-
tients who underwent a mastectomy between 2003 and
2012. None of the patients had previously undergone sur-
gery involving the breast and they did not receive preopera-
tive treatment. Tumour subtype scoring of luminal (n = 66;
luminal A + B) and HER2 (n = 54) was performed based on
estrogen receptor (ER), progesterone receptor (PGR), hu-
man epidermal receptor-2 (HER2), and an average Ki67 ex-
pression in accordance with St. Gallen International Breast
Cancer Guidelines [49]. A HER2 gene copy score of two
was evaluated by DNA FISH where a value <2.2 was con-
sidered negative and ≥2.2 was considered positive. For im-
munohistochemical staining and analysis, the paraffin
tissue sections (4 μm) were deparaffinized in xylene and
rehydrated in a graded series of ethanol-aqueous solutions.
Antigen retrieval was carried out in 10 mM citrate buffer
(pH 6.0) by heating the slides for 20 minutes in a micro-
wave oven. Endogenous peroxidase activity was blocked by
incubating the sections in 3 % hydrogen peroxide in Tris-
buffered saline for 10 minutes. The primary antibodies
were incubated overnight. The following primary anti-
bodies were used: mouse monoclonal anti-phospho-
histone H2AX (Ser139, Millipore; diluted 1/2000) and
rabbit polyclonal anti-phospho-RPA32 (Thr21, Abcam, di-
luted 1/250). Normal non-immune serum served as a
negative control. The primary antibodies were incubated
overnight, followed by detection using the Vectastain Elite
kit according to the manufacturer’s instructions (Vector
Laboratories, Burlingame, CA, USA) and nickel sulphate
enhancement without nuclear counterstaining, as de-
scribed [2]. Immunostaining patterns on each slide were
scored by an experienced oncopathologist based on the
fraction of positive nuclear staining signals (counting a
minimum of 300 epithelium or tumour cell nuclei per
slide) and the threshold for scoring the categories of
positivity was as follows: <2 % positive nuclei; 2–10 %
positive nuclei; and >10 % positive nuclei.
Breast cancer subtype classification and APOBEC3
mutation pattern detection
Data on breast cancer tumours (n = 755) were obtained
from TCGA Research Network (http://cancergenome.-
nih.gov/). Tumours were previously divided into subtypes
HER2, basal, luminal A, luminal B and normal based on
the PAM50 method [21]. Primary data, including SNP6
copy number profiles, mutation calls and APOBEC3 en-
richment values, were obtained from TCGA data version
2016_01_28. The APOBEC3 enrichment as a numeric
value for the strength of APOBEC3 mutagenesis is calcu-
lated similarly to [9] as:
E ¼ mutationsTCW X contextC
mutationsC X contextTCW
The parameter ‘mutationsTCW’ displays the number
of mutated cytosines in a TCW motif or mutated
guanines in a WGA motif. ‘MutationsC’ represents
the total number of mutated cytosines (or guanines),
‘contextTCW’ represents the total number of TCW
(or WGA) motifs and context, the total number of
cytosines (or guanines) in a specific region centred
within 20 nucleotides before and 20 nucleotides after
the mutated cytosines (or guanines).
Tumour samples that were significantly enriched for
APOBEC3 signature mutations (Benjamini–Hochberg
corrected p value <0.05) and fold enrichments >2 were
classified as ‘APOBEC high’, and the rest as ‘APOBEC
low’. To test whether genes were associated with APO-
BEC3 enrichment, a permutation test was carried out
with 100,000 permutations, randomly shuffling the labels
between ‘APOBEC high’ and ‘APOBEC low’ samples. The
entire cohort was first tested together to determine which
genes were significantly associated, following which the test
was performed again for each gene within each subtype.
Additional files
Additional file 1: Figure S1. APOBEC3B expression and activity in
breast cancer cell lines. a Boxplot showing number of SCNA breakpoints
in APOBEC high versus APOBEC low samples. b APOBEC3 isoform expression
in 15 breast cancer cell lines (gene expression data for APOBEC3B extracted
from CCLE_Expression_Entrez_2012-10-18.res:Gene-centric RMA-normalized
mRNA expression data). HER2+ cell lines (red), basal cell lines (black), luminal
cell lines (green). SKBR3 cells have a null mutation for APOBEC3B. c APOBEC3B
was depleted from MDA-MB-453, HCC1569 and BT474 cells by RNAi for 72 h,
followed by lysis and APOBEC3 cytidine deamination assay. d MDA-MB-453,
HCC1569 and BT474 cells were treated as in c followed by quantitative PCR
for APOBEC3B to determine the extent of knockdown. e Eight cell lines were
lysed and subjected to oligonucleotide-based cytidine deamination assay for
APOBEC3 activity using probe 1. f Eight cell lines were lysed and subjected
to oligonucleotide-based cytidine deamination assay for APOBEC3 activity
using probe 2. g Spearman rank correlation between APOBEC3 activity and
APOPEC3B mRNA expression in the panel of 15 cell lines used in Fig. 2
(r = 0.8, p = 0.0016). h Spearman rank correlation between the fraction
of G1 nuclear bodies and the APOPEC3B mRNA expression level in
the panel of 15 cell lines used in Fig. 2. i BT474 cells were treated
with 300 μM nucleosides for 48 h. Cell viability was determined by
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CellTiter-Glo. j BT474 cells were treated with 300 μM nucleosides
followed by analysis of cell cycle distribution by FACS. (TIF 35303 kb)
Additional file 2: Figure S2. Induction of replication stress in cell lines
using cytotoxic drugs a MCF10A cells, b MCF7 cells, c HCC1419 cells,
d MDA-MB-134 cells and e SKBR3 cells were treated with the indicated
drugs for 48 h prior to lysis and cytidine deamination assays for APOBEC3
activity. f MCF7 and CAL51 cells were treated with siRNAs targeting APOBEC3B
for 72 h followed by lysis and cytidine deamination assay for APOBEC3 activity.
g MCF7 and CAL51 cells were treated as in f followed by quantitative PCR to
determine levels of APOBEC3 depletion. The quantitative PCR was normalized
according to siNT control. (TIF 34618 kb)
Additional file 3: Figure S3. Cell viability following treatment of breast
cancer cell lines with cytotoxic drugs and nucleosides. a MCF10A cells, b
MDA-MB-134 cells, c HCC1419 cells and d HCC1428 cells were incubated
with the indicated drugs for 48 h, followed by cell viability determination
by CellTiter-Glo. e MCF10A cells were pre-treated with or without 300 μM
nucleosides for 24 h followed by 2 mM hydroxyurea treatment for an
additional 48 h. Cell cycle distribution was determined by FACS analysis.
(TIF 34064 kb)
Additional file 4: Figure S4. Cell cycle distribution following treatment
of breast cancer cell lines with cytotoxic drugs. a MCF10A cells were
incubated with the indicated drugs for 48 h prior to harvesting and
determination of cell cycle distribution by FACS analysis. b Histogram
representing the results shown in a displaying the percentage of cells
in each cell cycle phase in response to the different treatments. c HCC1419
cells were incubated with the indicated drugs for 48 h prior to harvesting
and determination of cell cycle distribution by FACS analysis. d MDA-MB-134
cells were incubated with the indicated drugs for 48 h prior to harvesting
and determination of cell cycle distribution by FACS analysis. (TIF 34520 kb)
Additional file 5: Figure S5. Titration of cytotoxic drugs in breast
cancer cell lines. a MCF10A cells were incubated with the indicated
concentrations of hydroxyurea for the indicated times prior to lysis and
cytidine deamination assays for APOBEC3 activity. b MCF10A cells were
treated with the indicated of doses of hydroxyurea for 48 h prior to lysis
and cytidine deamination assay for APOBEC3 activity. c MCF10A cells were
treated as in b followed by lysis and probing western blots with the indicated
antibodies. MCF10A cells were treated with the indicated concentrations of
aphidicolin (d), gemcitabine (e) and cisplatin (f) for 48 h prior to lysis and
cytidine deamination assays for APOBEC3 activity. (TIF 34567 kb)
Additional file 6: Figure S6. Replication stress correlates with APOBEC3
activation. a MCF7 cells were treated with the indicated drugs for 48 h
followed by fixation and immunofluorescence for Ser139 γH2AX and S4/8
RPA phosphorylation. Red asterisks indicate treatments inducing APOBEC3
activity levels and S4/8 RPA phosphorylation. Spearman rank correlations
between b the extent of RPA phosphorylation and APOBEC3B mRNA
expression, c the extent of RPA phosphorylation and APOBEC3G mRNA
expression, d the extent of RPA phosphorylation and APOBEC3 activity
(arbitrary units) from MCF10A cells treated in Fig. 3. e Quantitative PCR
validation of knockdown of RRM subunits to accompany Fig. 3f. 72 h
after siRNA transfection, MCF10A cells were lysed and mRNA isolated
followed by cDNA synthesis. Quantitative PCR was performed to determine
expression levels of RRM1, RRM2 and RRM2B. (TIF 38074 kb)
Additional file 7: Figure S7. Role of receptor tyrosine kinase signalling
in APOBEC3 activation. a BT474 and MDA-MB-361 cells were treated with
RNAi targeting ERBB2. After 72 h, cells were harvested, lysed and western
blots were probed with the indicated antibodies to determine the extent
of ERBB2 silencing. b BT474 cells were treated with 10 nM afatinib or 30
nM lapatinib for 24 h followed by lysis. Western blots were probed with
the indicated antibodies. c HCC1419 cells were treated with 2 mM
hydroxyurea in the presence or absence of 30 nM lapatinib. Following
mRNA isolation and cDNA synthesis, APOBEC3B mRNA expression levels were
determined by quantitative PCR. d HCC1419 cells were treated as in c and,
following lysis, oligonucleotide-based cytidine deamination assays
were performed for APOBEC3 activity using probe 1. e HCC1419 cells
were treated as in c and, following lysis, APOBEC3 cytidine deamination
assays were performed using probe 2. f HCC1419 cells were treated as in
c. Cells were lysed and western blots were probed with the indicated
antibodies. (TIF 34667 kb)
Additional file 8: Figure S8. Role of MAPK and PI3K pathways in
APOBEC3 activation. a BT474 cells were treated with 10 nM afatinib or 30
nM lapatinib for 24 h followed by cell viability determination by CellTiter-Glo.
b BT474 cells were treated with the indicated drugs for 48 h followed by cell
viability determination by CellTiter-Glo. c BT474 cells were treated as
in a and b followed by analysis of cell cycle distribution by FACS. d
MCF10A cells were treated with the indicated drugs as in Fig. 4g followed by
RNA isolation, cDNA synthesis and quantitative PCR to determine APOBEC3G
levels. e BT474 cells and f HCC1569 cells were treated with the indicated
drugs for 48 h. Cells were lysed and oligonucleotide-based cytidine
deamination assays were performed for APOBEC3 activity. (TIF 37363 kb)
Additional file 9: Figure S9. Role of MAPK and PI3K pathways in
hydroxyurea-induced APOBEC3 activation. a MCF10A cells were treated
with the indicated drugs for 48 h followed by cell viability determination
by CellTiter-Glo. b MCF7 cells were treated with the indicated drugs for
48 h followed by analysis of cell cycle distribution by FACS analysis. c MCF7
cells were transfected with PTEN siRNA. After 72 h the extent of knockdown
was determined by quantitative PCR. d PTEN levels were depleted from
MCF7 cells by RNAi. After 72 h cells were harvested and western blots were
probed with the indicated antibodies. e MCF7 cells were transfected with
PTEN siRNA or ubiquitin (UBB) control, followed by cell viability determination
by CellTiter-Glo. f MCF7 cells were treated as in c followed by cell
cycle distribution analysis by FACS. (TIF 35459 kb)
Additional file 10: Figure S10. Role for DNA damage signalling in
APOBEC3 activation. a BT474 cells were treated with the indicated doses
of Chk1 inhibitor CCT244747 followed by APOBEC3 cytidine deamination
assay. b ATR and CHEK1 were depleted from MCF10A cells by RNAi. After
24-h transfection, cells were treated with hydroxyurea for a further 48 h
prior to lysis and cytidine deamination assay for APOBEC3 actvity. c Validation
of the extent of silencing of ATR and CHEK1 in MCF10A cells. Cells were
treated with the indicated siRNAs for 72 h followed by mRNA isolation, cDNA
synthesis and quantitative PCR for ATR and CHEK1 mRNA expression levels. d
MCF10A cells were treated with hydroxyurea in the presence or absence of
Chk1 inhibitor UCN-01 for 48 h prior to mRNA isolation, cDNA synthesis and
quantitative PCR for APOBEC3B levels. e Eight breast cancer cell lines were
treated with ten doses of CCT244747 for two population doublings followed
by sulforhodamine B staining and GI50 determination. f MCF10A cells were
treated with the indicated drugs for 48 h followed by cell viability
determination using CellTiter-Glo. g BT474 cells were treated with 9
μM CCT244747 followed by analysis of cell cycle distribution by FACS.
h MCF10A cells were treated with the indicated drugs for 48 h followed by
analysis of cell cycle distribution by FACS. (TIF 34524 kb)
Additional file 11: Figure S11. The HER2+ breast cancer subtype exhibits
high levels of γH2AX and RPA-P staining. a Examples of immunohistochemical
staining of normal breast and HER2+ tumour samples with Ser139 γH2AX and
RPA-P. b The percentages of cases scoring <2 %, 2–10 % and >10 % or more
positive for Ser139 γH2AX in each subtype. P= 3.314e-06, Fishers exact test,
comparing luminal versus HER2+ subtype exhibiting more than 10 % of cells
staining positive for Ser139 γH2AX. c The percentages of cases scoring <2 %,
2–10 % and >10 % or more positive for RPA-P in each subtype. (TIF 34565 kb)
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